PropertyValue
?:abstract
  • Coronavirus disease 2019 (COVID-19) occurred in several countries since the end of 2019 Some infected patients have severe complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome Effective treatment methods are urgently needed Several clinician groups are attempting to apply stem cells in seriously or critically ill patients with novel coronavirus infected pneumonia In this paper, we briefly discuss some related issues, such as subject selection, safety and efficacy evaluation, as well as risk management, which should be concerned during the clinical trials based on the defects in clinical trial protocols, and thus provided some advice for investigators © 2020, Chinese Journal of New Drugs Co Ltd All right reserved
is ?:annotates of
?:creator
?:journal
  • Chinese_Journal_of_New_Drugs
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Considerations on the clinical trials of mesenchymal stem cells for the treatment of novel coronavirus infected pneumonia in patients
?:type
?:who_covidence_id
  • #825266
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/m4nlh6xo>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/m4nlh6xo>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all